Cargando…

Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders

Hepatitis B vaccine induces the production of antibodies against hepatitis B surface antigen (anti-HBs) and prevents hepatitis B virus (HBV) infection. However, 5–10% of individuals cannot develop anti-HBs even after multiple vaccinations (HB vaccine non-responders). We developed an intranasal vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiraishi, Kana, Yoshida, Osamu, Imai, Yusuke, Akbar, Sheikh Mohammad Fazle, Sanada, Takahiro, Kohara, Michinori, Miyazaki, Takashi, Kamishita, Taizou, Miyake, Teruki, Hirooka, Masashi, Tokumoto, Yoshio, Abe, Masanori, Rubido, Julio Cesar Aguilar, Nieto, Gerardo Guillen, Hiasa, Yoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535445/
https://www.ncbi.nlm.nih.gov/pubmed/37766155
http://dx.doi.org/10.3390/vaccines11091479
_version_ 1785112631032414208
author Shiraishi, Kana
Yoshida, Osamu
Imai, Yusuke
Akbar, Sheikh Mohammad Fazle
Sanada, Takahiro
Kohara, Michinori
Miyazaki, Takashi
Kamishita, Taizou
Miyake, Teruki
Hirooka, Masashi
Tokumoto, Yoshio
Abe, Masanori
Rubido, Julio Cesar Aguilar
Nieto, Gerardo Guillen
Hiasa, Yoichi
author_facet Shiraishi, Kana
Yoshida, Osamu
Imai, Yusuke
Akbar, Sheikh Mohammad Fazle
Sanada, Takahiro
Kohara, Michinori
Miyazaki, Takashi
Kamishita, Taizou
Miyake, Teruki
Hirooka, Masashi
Tokumoto, Yoshio
Abe, Masanori
Rubido, Julio Cesar Aguilar
Nieto, Gerardo Guillen
Hiasa, Yoichi
author_sort Shiraishi, Kana
collection PubMed
description Hepatitis B vaccine induces the production of antibodies against hepatitis B surface antigen (anti-HBs) and prevents hepatitis B virus (HBV) infection. However, 5–10% of individuals cannot develop anti-HBs even after multiple vaccinations (HB vaccine non-responders). We developed an intranasal vaccine containing both HBs antigen (HBsAg) and HB core antigen (HBcAg) and mixed it with a viscosity enhancer, carboxyl vinyl polymer (CVP-NASVAC). Here, we investigated the prophylactic capacity of CVP-NASVAC in HB vaccine non-responders. Thirty-four HB vaccine non-responders were administered three doses of intranasal CVP-NASVAC. The prophylactic capacity of CVP-NASVAC was assessed by evaluating the induction of anti-HBs and anti-HBc (IgA and IgG) production, HBV-neutralization activity of sera, and induction of HBs- and HBc-specific cytotoxic T lymphocytes (CTLs). After CVP-NASVAC administration, anti-HBs and anti-HBc production were induced in 31/34 and 27/34 patients, respectively. IgA anti-HBs and anti-HBc titers significantly increased after CVP-NASVAC vaccination. HBV-neutralizing activity in vitro was confirmed in the sera of 26/29 CVP-NASVAC-administered participants. HBs- and HBc-specific CTL counts substantially increased after the CVP-NASVAC administration. Mild adverse events were observed in 9/34 participants; no serious adverse events were reported. Thus, CVP-NASVAC could be a beneficial vaccine for HB vaccine non-responders.
format Online
Article
Text
id pubmed-10535445
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105354452023-09-29 Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders Shiraishi, Kana Yoshida, Osamu Imai, Yusuke Akbar, Sheikh Mohammad Fazle Sanada, Takahiro Kohara, Michinori Miyazaki, Takashi Kamishita, Taizou Miyake, Teruki Hirooka, Masashi Tokumoto, Yoshio Abe, Masanori Rubido, Julio Cesar Aguilar Nieto, Gerardo Guillen Hiasa, Yoichi Vaccines (Basel) Article Hepatitis B vaccine induces the production of antibodies against hepatitis B surface antigen (anti-HBs) and prevents hepatitis B virus (HBV) infection. However, 5–10% of individuals cannot develop anti-HBs even after multiple vaccinations (HB vaccine non-responders). We developed an intranasal vaccine containing both HBs antigen (HBsAg) and HB core antigen (HBcAg) and mixed it with a viscosity enhancer, carboxyl vinyl polymer (CVP-NASVAC). Here, we investigated the prophylactic capacity of CVP-NASVAC in HB vaccine non-responders. Thirty-four HB vaccine non-responders were administered three doses of intranasal CVP-NASVAC. The prophylactic capacity of CVP-NASVAC was assessed by evaluating the induction of anti-HBs and anti-HBc (IgA and IgG) production, HBV-neutralization activity of sera, and induction of HBs- and HBc-specific cytotoxic T lymphocytes (CTLs). After CVP-NASVAC administration, anti-HBs and anti-HBc production were induced in 31/34 and 27/34 patients, respectively. IgA anti-HBs and anti-HBc titers significantly increased after CVP-NASVAC vaccination. HBV-neutralizing activity in vitro was confirmed in the sera of 26/29 CVP-NASVAC-administered participants. HBs- and HBc-specific CTL counts substantially increased after the CVP-NASVAC administration. Mild adverse events were observed in 9/34 participants; no serious adverse events were reported. Thus, CVP-NASVAC could be a beneficial vaccine for HB vaccine non-responders. MDPI 2023-09-12 /pmc/articles/PMC10535445/ /pubmed/37766155 http://dx.doi.org/10.3390/vaccines11091479 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shiraishi, Kana
Yoshida, Osamu
Imai, Yusuke
Akbar, Sheikh Mohammad Fazle
Sanada, Takahiro
Kohara, Michinori
Miyazaki, Takashi
Kamishita, Taizou
Miyake, Teruki
Hirooka, Masashi
Tokumoto, Yoshio
Abe, Masanori
Rubido, Julio Cesar Aguilar
Nieto, Gerardo Guillen
Hiasa, Yoichi
Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
title Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
title_full Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
title_fullStr Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
title_full_unstemmed Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
title_short Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
title_sort intranasal hbsag/hbcag-containing vaccine induces neutralizing anti-hbs production in hepatitis b vaccine non-responders
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535445/
https://www.ncbi.nlm.nih.gov/pubmed/37766155
http://dx.doi.org/10.3390/vaccines11091479
work_keys_str_mv AT shiraishikana intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT yoshidaosamu intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT imaiyusuke intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT akbarsheikhmohammadfazle intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT sanadatakahiro intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT koharamichinori intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT miyazakitakashi intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT kamishitataizou intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT miyaketeruki intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT hirookamasashi intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT tokumotoyoshio intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT abemasanori intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT rubidojuliocesaraguilar intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT nietogerardoguillen intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders
AT hiasayoichi intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders